biostudies-literatureSheng XScience and Technology Commission of Shanghai MunicipalityMultidisciplinary Cross Research Foundation of Shanghai Jiao Tong UniversityShanghai Collaborative Innovation Center for Translational MedicineShanghai Natural Science FoundationNational Natural Science Foundation of Chinathe Shanghai Rising Stars of Medical Talent Youth Development Program for Outstanding Youth Medical TalentsClinical Research Plan of SHDCShanghai Municipal Key Clinical Specialtythe Nurturing Fund of Renji Hospital205https://www.ebi.ac.uk/biostudies/studies/S-EPMC8220716biostudies-literatureUnknown40(1)<h4>Background</h4>Triple negative breast cancer (TNBC) is a subtype of breast cancer with poor prognosis and lack of effective treatment target. Here we screened differentially expressed lncRNAs through bioinformatics analysis and identified CARMN as a downregulated lncRNA which is lowest expressed in TNBC. We aimed to identify the potential role and molecular mechanisms of CARMN in TNBC.<h4>Methods</h4>Predictive value of CARMN was explored in breast cancer cohorts. TNBC cell lines with CARMN overexpression or CARMN silence and were used for in vitro and in vivo experiments. RNA-seq of CARMN overexpressed cells was performed for exploring downstream of CARMN.<h4>Results</h4>CARMN is downregulated at different phase of malignant transformation of breast tissue. CARMN can predict both bettJournal of experimental & clinical cancer research : CRLncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication.PMC8220716ZH2018QNA42PYMDT-0022018-1682002777YG2019QNA2619ZR1431100TM201908SHDC2020CR3003A20DZ2201600Sheng XZhou LYin WLu JXu SDu YLin YSha RPeng JYang FWu YDai HfalseLncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication.<h4>Background</h4>Triple negative breast cancer (TNBC) is a subtype of breast cancer with poor prognosis and lack of effective treatment target. Here we screened differentially expressed lncRNAs through bioinformatics analysis and identified CARMN as a downregulated lncRNA which is lowest expressed in TNBC. We aimed to identify the potential role and molecular mechanisms of CARMN in TNBC.<h4>Methods</h4>Predictive value of CARMN was explored in breast cancer cohorts. TNBC cell lines with CARMN overexpression or CARMN silence and were used for in vitro and in vivo experiments. RNA-seq of CARMN overexpressed cells was performed for exploring downstream of CARMN.<h4>Results</h4>CARMN is downregulated at different phase of malignant transformation of breast tissue. CARMN can predict both bett2021-01-01T00:00:00Z2021 Jun2026-05-09T09:03:48.647Z2022-02-10T16:44:38.717ZS-EPMC82207163416241810.1186/s13046-021-02015-4